Abstract:Abstract BACKGROUND Prior exposure to advanced therapies (ADT) is associated with reduced response to future therapies in patients with ulcerative colitis (UC). Therapy persistence is a proxy of real-world treatment performance. This study compared persistence among ADT-experienced patients with UC initiated on ustekinumab (anti-interleukin 12/23 antibody), or adalimumab (anti-tumor necrosis factor biologic). METHODS Adults with UC initiated on ustekinumab or adalimumab (index date) between 10/21/2019 and 03/02/2022 were selected from the IQVIA PharMetrics® Plus database. Patients were ADT-experienced (i.e., ≥1 claim for a non-index UC-indicated ADT) in the 12-month baseline period before the index date. Patients with other auto-immune diseases during the baseline period were excluded. Cohorts were balanced on baseline characteristics using inverse probability of treatment weights. Persistence was defined as the absence of gaps between days of therapy supply of >120 days for ustekinumab or >60 days for adalimumab. Composite endpoints of being persistent while on monotherapy (no immunomodulators or index ADT) and persistent while corticosteroid-free (<14 consecutive days of corticosteroid supply after day 90 post-index) were also assessed. Persistence endpoints were described post-maintenance phase until the earlier of 12 months, end of insurance eligibility, or data using weighted Kaplan-Meier analyses and weighted Cox proportional hazards models adjusted for the use of ≥2 biologics and class of biologics used pre-index. RESULTS There were 693 and 254 patients in the weighted ustekinumab versus adalimumab cohorts, respectively (Fig. 1). At 12 months after the maintenance phase start, 78.1% of the ustekinumab cohort and 59.2% of the adalimumab cohort were persistent on the index biologic; persistence was 2.44 times higher in the ustekinumab cohort relative to the adalimumab cohort (p-value: <0.001; Fig. 2a). Moreover, 66.7% of the ustekinumab cohort and 40.5% of the adalimumab cohort persisted on the index biologic while on monotherapy; persistence while on monotherapy was 2.53 times higher in the ustekinumab cohort relative to the adalimumab cohort (p-value: <0.001; Fig. 2b). Finally, 48.0% of the ustekinumab cohort and 42.8% of the adalimumab cohort were persistent while corticosteroid-free; persistence while corticosteroid-free was 1.24 times higher in the ustekinumab cohort relative to the adalimumab cohort (p-value 0.0447; Fig. 2c). CONCLUSIONS ADT-experienced patients with UC treated with ustekinumab were more persistent, including persistent while on monotherapy and while corticosteroid-free than patients treated with adalimumab. These findings may aid healthcare providers in choosing a biologic for ADT-experienced patients with UC. Figure 1 Selected baseline characteristics in weighted ustekinumab and adalimumab cohorts Figure 2 Persistence in weighted ustekinumab and adalimumab cohorts: a) persistent on index biologic, b) persistent and on monotherapy, c) persistent and corticosteroid-free

P618 Comparison of vedolizumab and ustekinumab treatment persistence in anti-TNF experienced Crohn's Disease patients

P610 Ustekinumab demonstrates superior treatment persistence over anti-TNF in Crohn’s disease patients previously treated with vedolizumab

P603 Comparison of the safety and efficacy of ustekinumab and vedolizumab in patients with Crohn’s disease. - A systematic review and meta-analysis of propensity score matched cohort studies

Meta‐analysis: Persistence of advanced therapies in the treatment of inflammatory bowel disease

P665 Which second-line biologic after anti-TNF failure during Crohn’s disease: Ustekinumab or vedolizumab, a multicentre retrospective study

P877 A comparison of vedolizumab and ustekinumab treatment in patients with Ulcerative Colitis after failure of treatment with tumor necrosis factor inhibitor

P642 Effect of prior vedolizumab treatment on ustekinumab time-on-treatment in Crohn’s disease: a targeted literature review and statistical analyses

P1084 Persistence and efficacy of Ustekinumab in Crohn's disease after antiTNF failure. May the response of the second biologic therapy be better than the first one?

P784 Efficacy of ustekinumab in biologically naïve patients with Inflammatory Bowel Disease

P1028 Clinical decision support tool for vedolizumab can predict treatment persistence in Crohn's disease but not in ulcerative colitis

Real-World Persistence of Ustekinumab in the Treatment of Inflammatory Bowel Disease

P703 Comparison of infliximab and adalimumab therapies Persistence in patients with Ulcerative Colitis: Results from a Single Tertiary Turkish IBD Center Cohort

P435 Real-world comparison of effectiveness between ustekinumab and a second anti-TNF agent in patients with symptomatic stenosing Crohn's disease after failure of a first anti-TNF agent: results of the USTEKNOSIS study

P688 Comparative Effectiveness of Ustekinumab Versus Vedolizumab in Treating Crohn’s Disease After Failure of Anti-TNF Agents: Real-World Evidence

Vedolizumab versus ustekinumab in Crohn's disease with prior anti-tumor necrosis factor failure: an updated meta-analysis

P510 Relapse rate following withdrawal of vedolizumab and ustekinumab in patients with inflammatory bowel disease. The VEDUST-EXIT study

REAL-WORLD TREATMENT PERSISTENCE AMONG ADVANCED THERAPY-EXPERIENCED PATIENTS WITH ULCERATIVE COLITIS INITIATED ON USTEKINUMAB OR ADALIMUMAB

P334 Effectiveness and safety of ustekinumab in Crohn’s disease: short and long-term results of a multi-refractory cohort

P552 Clinical factors associated with ustekinumab therapy persistence in a refractory Crohn’s disease cohort

P629 Real-life treatment persistence and treatment outcomes of Finnish patients with Inflammatory Bowel Disease receiving vedolizumab as first-line biological treatment

P539 Assessment of VEdolizumab aNd Ustekinumab in Elderly patients with Crohn’s disease (CD): the IG-IBD AVENUE study